CD8A and neoplasm: This is supported by our in vivo data showing uniform distribution of immune activation markers (CD8, GZMB) throughout tumor sections in high-dose PD-1-0520-treated mice (Figure 7), whereas antibody therapies frequently exhibit heterogeneous efficacy in solid tumors.